Nodular melanoma presenting with rapid progression and widespread metastases: a case report
© Erkurt et al; licensee BioMed Central Ltd. 2009
Received: 29 August 2008
Accepted: 06 February 2009
Published: 06 February 2009
Melanoma is responsible for 1% to 2% of all cancer deaths around the world. Nodular melanoma often carries a poor prognosis because of no prodromal radial growth phase, early distant metastasis and significant tumor volume.
We present a case of progressive melanoma. A 51-year-old man was admitted to our hospital with dyspnea and skin lesions. These were multiple, dark colored, firm, and nodular and varied in size. He was diagnosed with melanoma. Temozolomide was administered, but he died of respiratory failure within a week after diagnosis.
Nodular melanoma tends to spread rapidly and eventually metastasize to vital organs. It may be fatal within months of recognition.
Melanoma is a neoplasm derived from melanocytes of the skin and other sites. It accounts for 1% to 3% of all malignancies and 1% to 2% of all cancer deaths worldwide. Recently, melanoma has become a major health problem in many countries. The worldwide incidence rate is increasing much more rapidly than for any other malignancies . The mortality and morbidity rate from melanoma has risen about 2% annually since 1960 . Projections were for 59,940 cases of melanoma and 48,290 cases of in situ melanoma to be newly diagnosed in the USA in 2007. Of these, 8110 cases were expected to be fatal .
The lifetime risk of melanoma is 1:70 in the population of the USA and will probably be 1:50 in 2010 . According to the American Joint Committee on Cancer, melanomas are classified as superficial spreading melanoma, nodular melanoma, lentigo melanoma, acral lentiginous melanoma and unclassified melanoma. Nodular melanoma, comprising 10% to 15% of cutaneous melanomas, is the second most common variety of melanocytic neoplasms and occurs less commonly than superficial spreading melanoma. The median age of onset is 49 years. The duration of lesions before diagnosis is relatively short, ranging from a few months to 2 years . Nodular melanoma often presents as an expanding darkly pigmented cutaneous nodular lesion, usually found on the sun-exposed areas of the skin, with far fewer such lesions occurring in covered areas. The most common sites are the trunk in men and the legs in women. Major risk factors for nodular melanoma include the presence of multiple dysplastic nevi, positive family history, light colored skin with an inability to tan, and excessive sun exposure. Nodular melanoma is known to present with greater thickness than the other subtypes of melanoma, therefore, it often carries a poorer prognosis . Even in its early stages, it has the potential to metastasize to the vital organs . Herein, we present a patient with melanoma which was associated with highly invasive and aggressive behavior.
Nodular melanoma is more common in men than women. The trunk is a common site and a discrete nodule with dark black/brown pigmentation is typical. Ulceration and bleeding are common complications. Nodular melanoma has a peak incidence around 50 years of age . It arises in normal skin or in a precursor lesion, but without an intervening radial growth phase. A widely accepted histopathological definition of nodular melanoma is a melanoma that lacks an in-situ component beyond three rete ridges of the invasive vertical growth phase; thus, even in its early stages, nodular melanoma has the potential to metastasize [6, 7]. Acral lentiginous melanoma is most frequent in the 60 to 70 year age group. It was so named because of its predilection for acral (distal) areas of the body, particularly the palms, soles and subungual areas, and its distinct radial or "lentiginous" growth phase. Its diagnosis is described as being based on its histological, intradermal features showing a diffuse proliferation of large atypical melanocytes along the epidermal-dermal junction which is dispersed in a lentiginous pattern with marked acanthosis and elongation of the rete ridges. Acral lentiginous melanoma is the only sub-type of melanoma that occurs at the same rate in all races, predominantly on an area that seldom receives much sun exposure. It has been suggested that the etiology is different from that of nodular melanoma or that sun exposure is a lesser risk factor than melanoma elsewhere. Also, various histopathologic features including nodular and acral lentiginous subtypes, vertical growth phase, high mitotic activity and the presence of microscopic satellites are associated with poor prognosis . Metastatic melanoma usually involves draining lymph nodes and occasionally adjacent skin first, but eventually metastasizes to distant visceral sites. The skin and subcutaneous lymph nodes (59%) are most commonly involved followed by lung (36%), brain (20%), liver (20%), bone (17%) and others (12%) [6, 7]. In our patient, metastatic lesions were seen in the lungs, pleura, heart and brain at the time of diagnosis. Although the diagnosis was not confirmed histologically, widespread metastases that developed in the patient within a short period of time strongly suggested melanoma. In the literature [6, 7], melanoma is reported to develop metastases in every organ. Similarly, the patient developed rapidly progressive vital organ metastases.
Prognosis according to Breslow thickness in melanoma
< 1 mm
> 4 mm
Despite research, no consensus has been reached as to the optimal management, There is level I evidence for the treatment of stage III and stage IV patients. Traditionally, management of melanoma metastatic to distant sites involves either a single-drug or multi-drug chemotherapeutic regimen. However, complete response rates have been poor (< 6%) with a minimal increase in the median survival [9, 10]. Chemotherapy was administered immediately after the diagnosis of melanoma was suggested, but he died of respiratory failure because of the rapidly progressive course of disease with widespread pulmonary, brain, heart and cutaneous metastases.
Tumor thickness, level of invasion, and number of involved nodes are the most powerful prognostic indicators in nodular melanoma. As described in our patient, nodular melanoma has a strong tendency for widespread dissemination and metastasis to vital organs. Despite increased therapeutic options for the treatment of advanced melanoma, the results are disappointing in patients with widespread metastases.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
erythrocyte sedimentation rate
- Burton RC, Coates MS, Hersey P, Roberts G, Chetty MP, Chen S, Hayes MH, Howe CG, Armstrong BK: An analysis of a melanoma epidemic. Int J Cancer. 1993, 55: 765-770. 10.1002/ijc.2910550512.View ArticlePubMedGoogle Scholar
- Rigel DS, Carucci JA: Malignant melanoma: prevention, early detection, and treatment in the 21st century. CA Cancer J Clin. 2000, 50: 215-236. 10.3322/canjclin.50.4.215.View ArticlePubMedGoogle Scholar
- Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics. CA Cancer J Clin. 2007, 57: 43-66. 10.3322/canjclin.57.1.43.View ArticlePubMedGoogle Scholar
- Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001, 19: 3635-3648.PubMedGoogle Scholar
- Bergenmar M, Ringborg U, Mansson Brahme E, Brandberg Y: Nodular histogenetic type the most significant factor for thick melanoma: implications for prevention. Melanoma Res. 1998, 8: 403-411. 10.1097/00008390-199810000-00004.View ArticlePubMedGoogle Scholar
- Balch CM, Soong SJ, Murad TM, Smith JW, Maddox WA, Durant JR: A multifactorial analysis of melanoma. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol. 1983, 1: 126-134.PubMedGoogle Scholar
- Barth A, Wanek LA, Morton DL: Prognostic factors in 1521 melanoma patients with distant metastases. J Am Coll Surg. 1995, 181: 193-201.PubMedGoogle Scholar
- Bristow IR, Acland K: Acral lentiginous melanoma of the foot and ankle: A case series and review of the literature. J Foot Ankle Res. 2008, 1: 11-10.1186/1757-1146-1-11.View ArticlePubMedPubMed CentralGoogle Scholar
- Legha SS, Ring S, Papadoupoulos N, Plager C, Chawla S, Benjamin R: A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer. 1989, 64: 2024-2029. 10.1002/1097-0142(19891115)64:10<2024::AID-CNCR2820641010>3.0.CO;2-V.View ArticlePubMedGoogle Scholar
- McClay EF, Mastrangelo MJ, Berd D, Bellet RE: Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer. 1992, 50: 553-556. 10.1002/ijc.2910500410.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.